Metabolomic Study for Localized Prostate Cancer

A Pilot Study to Establish a Standardized Protocol for Omic Analysis of Patients With Clinically Localized Prostate Cancer Receiving Radiation Therapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01968538

Enrollment

400

Registered

2013-10-24

Start date

2009-01-31

Completion date

2024-12-31

Last updated

2023-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease. Recent advances in omic analysis may offer additional information to the physician about prognosis and radiation response. We propose to establish a protocol to incorporate omic analysis into the evaluation and treatment of patients with prostate cancer.

Interventions

RADIATIONRadiation Therapy

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 100 Years

Healthy volunteers

Yes

Inclusion criteria

* Males who are older than 18 years old, * with clinically localized prostate cancer * are receiving radiation therapy

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
molecular changes in biofluid	5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026